MI-2 Autoantibodies
Anti-MI-2 antibody test is highly specific for dermatomyositis, but the sensitivity is low. Only 25% of dermatomyositis patients have the antibodies. These auto-antibodies are associated with acute-onset classic dermatomyositis, including V-neck sign and shawl rash. In dermatomyositis muscle enzyme levels are often abnormal, increased creatine kinase and aldolase, or may increase in AST (aspartate aminotransferase) and LDH (lactate dehydrogenase.
Dermatomyositis (DM) is an autoimmune disease characterized by muscle weakness and distinctive skin rash (characteristic “heliotrope” rashes). It is a rare disease occurring in 5-10 per million population, mostly in adults 40-60, children 5-15 years old, and more in females than males.
Dermatomyositis results from humoral attack against the muscle capillaries and small arterioles (endothelium of endomysial blood vessels) and is an ongoing micro-angiopathy.
Mi-2, the dermatomyositis specific auto-antigen, is a component of a complex containing histone deacetylase and nucleosome activities. Recently, research evidence has been accumulated on the clinical significance of dermatomyositis specific antibodies including autoantibodies against melanoma differentiation antigen 5 (MDA5), transcription intermediary factor 1 (TIF1), nuclear matrix protein 2 (NXP2) and small ubiquitin-like modifier enzyme activities (SAE).
Anti-MDS5 antibodies are highly specific in correlating clinical amyopathic dermatomyositis patients with progressive interstitial lung disease (ILD).
Anti-TIF1 antibodies are present in juvenile and adult dermatomyositis. It is also correlated with malignancy in adult dermatomyositis.
Anti-NXP2 antibodies are associated with calcinosis and severe muscle disease.
A small number of patients with anti-SAE tend to present with skin disease first and then progress to muscle weakness with systemic symptoms including dysphagia.
All of these auto-antibodies are useful in comprehending the heterogeneous spectrum of dermatomyositis.
- As an aid to diagnosis of dermatomyositis, in conjunction with chest X-ray, electromyography, MRI and skin/muscle biopsy
- As an aid in diagnosis of polymyositis and myositis
Positive: may be indicative of dermatomyositis, along with appropriate symptoms.
Negative (Non-reactive)
Immunoprecipitation (IPP).
Serum (SST) or plasma (EDTA).
Stability
- Ambient: 1–3 days
- Refrigerated: 7 days
- Lancet. Jan 1;355(919):53-7 [PMID: 1061591]
- J Clin Invest. 1995 Oct;96(4):1730-7. [PMID: 5760064]
- Clin Dermatol. 2006 Sep-Oct;24(5):363-73. [PMID: 1966018]
- N Engl J Med. 1975 Feb 13;292(7):344-7. [PMID: 1090849]
- N Engl J Med.1975 Feb 20;292(8)403-7. [PMID: 1089199]
- Medicine (Baltimore). 1966 Jul;45(4):261-89. [PMID: 5946688]